20090-69-1

Basic information

• Product Name: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)
• Synonyms: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI);5-Amino-2-chloro-4-methylpyrimidine;2-chloro-4-methyl-pyrimidin-5-ylamine;2-Chloro-4-MethylpyriMidin-5-aMine;NSC 243816;5-PyriMidinaMine, 2-chloro-4-Methyl-
• CAS NO: 20090-69-1
• Molecular Formula: C₅H₆ClN₃
• Molecular Weight: 143.57424
• Product Categories: PYRIMIDINE
• Mol File: 20090-69-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 93.5℃
• Boiling Point: 309.4 °C at 760 mmHg
• Flash Point: 140.9 °C
• Appearance: /
• Density: 1.349 g/cm³
• Vapor Pressure: 0.00064mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.36±0.29(Predicted)
• CAS DataBase Reference: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)(20090-69-1)
• EPA Substance Registry System: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)(20090-69-1)

Safety Data

• Hazardous Substances Data: 20090-69-1(Hazardous Substances Data)

Usage

General Description

5-Pyrimidinamine, 2-chloro-4-methyl- (9CI) is a chemical compound with the molecular formula C5H5ClN4. It is a derivative of pyrimidine and contains a chlorine and a methyl group. 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI) is a white crystalline solid that is used in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the development of anti-cancer, anti-inflammatory, and anti-viral drugs. Additionally, it is used as a building block in the production of various organic compounds and as a research tool in chemical and biological studies. The safety and environmental impact of this chemical compound should be carefully considered and managed during its handling and use.

InChI:InChI=1/C5H6ClN3/c1-3-4(7)2-8-5(6)9-3/h2H,7H2,1H3

Upstream product

• 16632-21-6 5-nitro-6-methyluracil 
• 626-48-2 6-Methyluracil 
• 13162-27-1 5-amino-2,4-dichloro-6-methylpyrimidine 
• 13162-26-0 2,4-dichloro-6-methyl-5-nitropyrimidine 
• 7732-18-5 water 

Downstream Products

• 3438-61-7 5-amino-4-methylpyrimidine 
• 89181-77-1 4-methylpyrimidine-2,5-diamine 
• 633328-96-8 N-(2-chloro-4-methylpyrimidin-5-yl)acetamide 
• 1393181-01-5 5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 
• 633328-98-0 5-chloro-1H-pyrazolo[4,3-d]pyrimidine 
• 858268-91-4 4-nitro-benzenesulfonic acid-(4-methyl-2-methylsulfanyl-pyrimidin-5-ylamide) 
• 272-57-1 1H-pyrazolo[4,3-d]pyrimidine 

Relevant articles and documents

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors

The invention relates to pyridopyrimidinone compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of Plk1.